Collectively, these data show that TKI-mediated BCR::ABL1 inhibition causes downregulation of key metabolic pathways, although not sufficiently to prevent LSC survival, suggesting that additional metabolism-targeting drugs may be required to effectively eradicate CML LSCs. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.